Head-to-head evidence
Fulzerasib vs Sotorasib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline
Fulzerasib
Developed by Innovent Biologics
NCT05756153 · Phase 1/2 · completed
The study was open-label, non-randomized, and had no comparator arm, with 47 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Interim analysis (ASCO 2024 late-breaking presentation, data cutoff before primary completion); single-arm response rate with no formal statistical threshold.
Next expected readout: March 2027 · NCT07492342 (registry estimate)
Sotorasib
Marketed by Amgen and partners
NCT04303780 · Phase 3 · completed
The 345 participants were randomized 1:1 to sotorasib or active-comparator docetaxel, but treatment assignment was not masked. The primary clinical endpoint, progression-free survival assessed by blinded independent central review, was met in favor of sotorasib, with median progression-free survival of 5.62 versus 4.47 months and a hazard ratio of 0.663 (p=0.002).
Next expected readout: October 2026 · NCT06333951 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fulzerasib's landscape · Sotorasib's landscape